LogicBio Therapeutics

96 articles about LogicBio Therapeutics

• LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates 

  12/17/2019

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has entered into an exclusive license with Oregon Health & Science University (“OHSU”) to intellectual property rights owned by OHSU while also extending  a sponsored research agreement

• LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates

  11/12/2019

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for the third quarter ended September 30, 2019

• LogicBio Therapeutics to Present at November Conferences

  11/7/2019

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences:

• LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress– Panel Presentation on AAV Manufacturing –

  10/16/2019

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the European Society of Gene and Cell Therapy (ESGCT) 27th Annual Congress, held in Barcelona, Spain, October 22-25, 2019.

• 

  LogicBio Plans First Clinical Trial for Gene Editing in Children

  3/8/2019

  Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children. 
• 

  A Record Year: A Look at the Biotech IPOs for Q4 2018

  12/27/2018

  The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion. 
• 

  Updated: BioSpace's List of October 2018 Life Sciences IPOs

  10/31/2018

  A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
• 

  A Look Back at October Life Sciences IPOs

  10/31/2018

  October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.

• Chardan Serves as Lead Manager for LogicBio Therapeutics

  10/22/2018

  Chardan announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.

• LogicBio Therapeutics Appoints Dean Falb, Ph.D., as Chief Scientific Officer

  5/23/2018

  Genome editing company adds drug development expert in pursuit of breakthrough medicines for pediatric patients

• LogicBio Therapeutics Launches Development Program in Methylmalonic Acidemia (MMA)

  5/9/2018

  Preclinical data demonstrate potential for LB-001 to address the underlying cause of MMA

• 

  Biotech Companies Continue to Shake Up Leadership with New Appointments

  5/8/2018

  There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.

• LogicBio Therapeutics Strengthens Leadership Team with Key Appointments

  5/2/2018

  LogicBio Therapeutics, Inc. announced the appointment of Sandra Poole as chief operating officer, and Paul Herzich as senior director of manufacturing.

• LogicBio Therapeutics Announces Expansion of Leadership Team Through Multiple Key Hires

  1/2/2018

  LogicBio Therapeutics today announced the expansion of its leadership team with the appointment of four seasoned industry leaders

• LogicBio Announces $50 Million In Financing To Develop Novel Gene Medicines For Pediatric Patients

  6/28/2017

• Arix Bioscience Leads $45 Million Series B Financing Round Into LogicBio

  6/28/2017